Table 3. Genes down-regulated (≥3-fold vs LPS activation alone) by PEITC in various human cells.
| Genesymbol | Gene name | Partial Gene Ontology term(www.geneontology.org) | Responsivecell lines | % change in “S”to 10 µM PEITC | H3 changes in PEITC- treated “S”* |
| CCL2 | Chemokine (C-C motif) ligand 2 | Inflammatory response; Chemokine activity | S/T | 82.43 | H3K27me3 |
| CD40 | CD40 antigen | Signal transduction; Immune response;Apoptosis | S/T | 49.52 | H3K27me3, H3K9me2 |
| CSF2 | Colony stimulating factor 2(granulocyte -macrophage) | Immune response; Cytokine andchemokine- mediated signaling pathway | S | 36.55 | NT |
| CXCL10 | Chemokine (C-X-C motif) ligand 10 | Inflammatory response; Chemokine activity | S/H/T | 91.63 | ND |
| IL8 | Interleukin 8 | Immune response; Cytokine activity | S/H | 82.43 | H3K27me3, H3Ac |
| MMP7§ | Matrix metalloproteinase 7 | Zinc-dependent endopeptidases | S | 36.87 | H3K27me3, H3Ac |
| MMP9 | Matrix metalloproteinase 9 | Zinc-dependent endopeptidases | S/T | 84.50 | ND |
| NFκB1 | Nuclear factor of kappa light chain geneenhancer in B-cells 1, p105 | DNA binding; Regulation of transcription | S/T | 41.98 | H3K27me3 |
| NFκBiα | Nuclear factor of kappa light chain geneenhancer in B-cells inhibitor, alpha | Nucleus; Protein binding; Cytoplasm;Regulation of cell proliferation;Protein-nucleus import, translocation | S/T | 38.44 | NT |
| REL | Reticuloendotheliosis oncogene | DNA binding; Regulation of transcription | S | 28.80 | ND |
| RELb | Avian reticuloendotheliosis viral (v-rel)oncogene related B | Transcription factor activity; Intracellular;T-helper 1 type immune reponse | S/T | 66.8 | ND |
| STAT1 | Signal transducer and activatorof transcription 1 | DNA binding; Regulation of transcription | S/H/T | 11.28 | H3K27me3 |
| TNFαip3 | Tumor necrosis factor, alpha-inducedprotein3 | Apoptosis; Zinc ion binding | S/T | 58.05 | NT |
Cell lines SW480, S; HT-29, H; THP-1, T.
All except MMP7 and MMP9 genes were tested in RAW macrophages in our previous report; Genes that were responsive in RAW cells but did not express/induce in any of the human cell lines are not listed here, but were previously reported as potential targets of PEITC (Dey et al., 2010).
§
Novel PEITC-mediated effect observed in the current study.
NT: Not Tested for H3 modification due to unsuccessful design of promoter primer.
ND: Tested, but none of the three H3 modifications were observed.
*
Information based on 5 h incubation with PEITC in SW480 cells.